Validation Data Gallery
|Sample-dependent, check data in validation data gallery|
13003-2-AP targets UBD in WB, IHC, IF,ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||UBD fusion protein Ag3680|
|Full Name||ubiquitin D|
|Calculated molecular weight||165 aa, 18 kDa|
|GenBank accession number||BC012472|
|Gene ID (NCBI)||10537|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
UBD, also named as FAT10, contains two ubiquitin-like domains. It is a ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. UBD also has important roles in cell mitosis, chromosome instability, apoptosis and immune response. UBD mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). It promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). UBD regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. It may be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T cell responses. UBD may be a marker for precancerous lesions and may promote cancer progression. This antibody is a rabbit polyclonal antibody raised against full length UBD of human origin.
J Toxicol Sci
Disruption of spindle checkpoint function ahead of facilitation of cell proliferation by repeated administration of hepatocarcinogens in rats.
Exp Toxicol Pathol
Aberrant cell cycle regulation in rat liver cells induced by post-initiation treatment with hepatocarcinogens/hepatocarcinogenic tumor promoters.
J Toxicol Sci
Fluctuations in cell proliferation, apoptosis, and cell cycle regulation at the early stage of tumor promotion in rat two-stage carcinogenesis models.
J Toxicol Sci
Aberrant activation of ubiquitin D at G2 phase and apoptosis by carcinogens that evoke cell proliferation after 28-day administration in rats.
J Appl Toxicol
Onset of hepatocarcinogen-specific cell proliferation and cell cycle aberration during the early stage of repeated hepatocarcinogen administration in rats.
c-Rel is dispensable for the differentiation and functional maturation of M cells in the follicle-associated epithelium.